Abstract:Immune checkpoint, PD-1, inhibitors, have been approved to treat advanced NSCLC patients without oncogenic driver in the second-line setting based on durable clinical benefit. It has been demonstrated that the overall mutational burden in tumor tissue was significantly associated with progression free survival (PFS) of advanced NSCLC patients treated with PD-1 inhibitor. However, tumor tissue may not be available from all patients at any time during PD-1 blockade therapy. Therefore, the purpose of this study was to explore the predictive value of mutation/neoantigen burden from ctDNA on efficacy of PD-1 inhibitors. We treated advanced NSCLC patients without oncogenic drivers with PD-1 inhibitor in the second or more line setting. The whole-exome of tumor tissues and ctDNA at baseline and ctDNA at every time of efficacy evaluation from these patients were sequenced by NGS. The hybrid-capture-enriched libraries were sequenced on the Illumina HiSeq 4000 platform with 75-base paired-end reads, sequencing depth was 300 for ctDNA whole-exome sequencing. We compared the results of whole-exome sequencing between patients who achieved objective response to PD-1 inhibitor and patients who experienced disease progression. Besides, we also compared the results of whole-exome sequencing between baseline ctDNA and ctDNA extracted at efficacy evaluation. Up to now, a total of 23 patients treated with PD-1 inhibitor received efficacy evaluation at least once in this study. Of them, 4 patients achieved partial response (PR), 3 patients achieved stable disease (SD). Of 4 patients with PR, 3 patients were found to harbor high mutation burden (more than 400 nonsynonymous mutations) from ctDNA and only 1 patient harbored mutation burden of less than 100 from ctDNA at baseline. We found the mutation or neoantigen burden from ctDNA changed during PD-1 blockade therapy. The efficacy of PD-1 inhibitor appeared to be more significantly associated with neoantigen burden rather than mutation burden. Only one ctDNA sample was found positive for MSH6 mutation (C1337X) and all baseline ctDNA samples were negative for microsatellite instability (MSI) status. Evaluating nonsynonymous mutation burden/neoantigen burden from ctDNA was feasible in advanced NSCLC patients treated with PD-1 inhibitors. The predictive value of neoantigen burden from ctDNA on the efficacy of PD-1 inhibitor may be better than that of mutation burden in advanced NSCLC. It may not be feasible to determine the status of mismatch-repair deficiency and MSI using ctDNA samples in advanced NSCLC. An expanded study is ongoing. More details will be presented in the conference.

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Molecular Analysis of Cell-Free DNA to Identify Distinct Molecular Mutational Burden and Its Effect on First-Line Chemotherapy in Patients with NSCLC from a Phase III Trial.

Detection and Dynamic Changes of Egfr Mutations from Circulating Tumor Dna As A Predictor of Survival Outcomes in Nsclc Patients Treated with First-Line Intercalated Erlotinib and Chemotherapy

Mutational Landscape of Circulating Tumor DNA Identifies Distinct Molecular Features Associated with Therapeutic Response in Patients with Metastatic Colorectal Cancer.

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

MA15.03 The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC

Association of Circulating Tumor DNA Clearance During Treatment with Improved Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients.

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

Predictive and Prognostic Value of Folate Receptor-Positive Circulating Tumor Cells in Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Abstract 2252: Correlation of Baseline Value of Folate Receptor-Positive Circulating Tumor Cells and Efficacy of Pemetrexed and Dynamic Monitoring Study in Non-Small Cell Lung Cancer Patients Receiving First-Line Platinum-Based Chemotherapy

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma

P1.01-037 Circulating Tumor DNA Clearance During Treatment Associates with Improved Progression-Free Survival

Cfdna Analysis to Reveal Association of Genomic Features with Chemotherapy Response and Survival in Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma.

Abstract 707: Combinatorial Assessment of Ctdna Release and Mutational Burden Predicts Clinical Outcome from Anti-Pd-(l)1 Therapies in Non-Small-cell Lung Cancer

Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Circulating Tumor DNA Clearance Predicts Prognosis Across Treatment Regimen in a Large Real-World Longitudinally Monitored Advanced Non-Small Cell Lung Cancer Cohort.

Circulating Tumor Cells Dynamics During Chemotherapy Predict Survival and Response in Advanced Non-Small-cell Lung Cancer Patients.

592P the Role of Early Change in Circulating Tumor DNA As a Potential Predictor of Response to Chemotherapy in Patients with Metastatic Colorectal Cancer